Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Jane4IceCream who wrote (64728)	10/8/1999 9:19:00 AM
From: ok1day	Read Replies (1) \| Respond to of 90042

What is the reason MM will keep ask same and move bid up? Thanks

To: Jane4IceCream who wrote (64728)	10/8/1999 9:28:00 AM
From: kathyh	Read Replies (1) \| Respond to of 90042

hi jane... imcl news Friday October 8, 7:31 am Eastern Time Company Press Release ImClone Initiates Enrollment in Phase II Clinical Trial of C225 in Combination With CPT-11 for Treatment of Patients With Refractory Colorectal Carcinoma NEW YORK--(BW HealthWire)--Oct. 8, 1999--ImClone Systems Incorporated (Nasdaq: IMCL - news) announced today the initiation of patient treatment in a multi-center Phase II clinical trial evaluating ImClone's lead cancer therapeutic, C225, in combination with the chemotherapeutic agent CPT-11 in 98 patients with refractory colorectal carcinoma. C225 is a monoclonal antibody that is an antagonist to the Epidermal Growth Factor receptor (EGFr), which is associated with the growth and survival of cancer cells in a variety of solid tumors, including colorectal, pancreatic and squamous cell head and neck carcinomas. ''Unfortunately, current therapies for colorectal carcinoma are usually ineffective in treating refractory disease. We hope to show in this trial that a combination of C225 and CPT-11 will result in an improved response rate in patients with refractory colorectal cancer,'' stated Harlan W. Waksal, M.D., Executive Vice President and Chief Operating Officer of ImClone Systems. ImClone has initiated two Phase III clinical trials evaluating C225 in combination with chemotherapy or with radiotherapy in patients with advanced squamous cell head and neck carcinoma. In addition, the Company has also initiated a Phase II clinical trial evaluating C225 in combination with chemotherapy in patients with refractory advanced squamous cell head and neck carcinoma. ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical company engaged in the research and development of novel cancer treatments. We focus on what we believe are three promising strategies for treating cancer: growth factor inhibitors, therapeutic vaccines and angiogenesis inhibitors. Except for the historical information contained herein, the matters discussed in this news release may include forward-looking statements. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company's business, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing, and the Company's ability to obtain additional financing to support its operations. The Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. -------------------------------------------------------------------------------- Contact: ImClone Systems Inc., New York Andrea Rabney, Senior Director of Corporate Development and Investor Relations, 212/645-1405 or Burns McClellan, Inc., New York Justin Jackson (media)/Ethan Denkensohn (investors), 212/213-0006 -------------------------------------------------------------------------------- More Quotes and News: Imclone Systems Inc (NasdaqNM:IMCL - news) Related News Categories: biotech, medical/pharmaceutical --------------------------------------------------------------------------------